Comparison · NCT04163458-3b21025a
MENOPUR Liquid vs MENOPUR Powder: Early Pregnancy Loss
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MENOPUR Liquid vs MENOPUR Powder: Early Pregnancy Loss. Trial comparisons, record NCT04163458-3b21025a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04163458-3b21025a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.195 | 0.132 | 0.277 | wilson | |
| Risk in group 2 | 0.227 | 0.159 | 0.314 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0326 | -0.139 | 0.0746 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.857 | 0.515 | 1.43 | log | |
| Odds ratio, group 1 over group 2 | 0.822 | 0.431 | 1.57 | log | |
| Number needed to treat, for one fewer participant with the outcome on MENOPUR Liquid than on MENOPUR Powder | 30.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MENOPUR Liquid | MENOPUR liquid (including placebo to MENOPUR powder) initiated at a fixed dose of 225 international units (IU) for first five stimulation days. From stimulation Day 6, dosing could be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose was 450 IU/day and the minimum dose was 75 IU/day. The dosing could continue for a maximum of 20 days.~MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL: Solution for injection in pre-filled pen, subcutaneous administration~Placebo (for MENOPUR powder and solvent for solution for injection): Solution for injection in vials (powder and diluent); subcutaneous administration | 22 | 113 | OG000 |
| Group 2 | MENOPUR Powder | MENOPUR powder (including placebo to MENOPUR liquid) initiated at a fixed dose of 225 IU for first five stimulation days. From stimulation Day 6, dosing could be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose was 450 IU/day and the minimum dose was 75 IU/day. The dosing could continue for a maximum of 20 days.~MENOPUR powder and solvent for solution for injection, 75 IU: Solution for injection in vials (powder and diluent), subcutaneous administration~Placebo (for MENOPUR solution for injection in pre-filled pen): Solution for injection in pre-filled pen, subcutaneous administration | 25 | 110 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Early Pregnancy Loss
- Description
- Number of participants with early pregnancy loss defined as a positive βhCG tests but no ongoing pregnancy.
- Time frame
- 8-9 weeks after blastocyst transfer (up to approximately 13 weeks after start of stimulation)
- Population
- Only participants who had a positive βhCG test were eligible.
Source ClinicalTrials.gov
Trial
- Title
- Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
- NCT number
- NCT04163458
- Phases
- PHASE3
- Conditions
- Infertility
- Interventions
MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen), Placebo (for MENOPUR powder and solvent for solution for injection)
- Lead sponsor
- Ferring Pharmaceuticals
- Results first posted
- 2023-11-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04163458?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04163458-3b21025a